Feasibility, phase I, and pharmacological study of aerosolized liposomal 9-nitro-20(S)-camptothecin in patients with advanced malignancies in the lungs

Annals of the New York Academy of Sciences

Volumn 922, Issue , 2000, Pages 352-354

  Verschraegen, C F ^a,c   Gilbert, B E ^a   Huaringa, A J ^b   Newman, R ^a   Harris, N ^b   Leyva, F J ^a   Keus, L ^b   Campbell, K ^a   Nelson Taylor, T ^a   Knight, V ^b  

^a UNIVERSITY OF TEXAS   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RUBITECAN;

ADULT; ADVANCED CANCER; AEROSOL; AGED; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; FEASIBILITY STUDY; FEMALE; FIRST PASS EFFECT; HUMAN; LUNG FUNCTION; LUNG LAVAGE; LUNG TUMOR; MALE; PHASE 1 CLINICAL TRIAL; TREATMENT OUTCOME;

EID: 0034514106     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2000.tb07063.x     Document Type: Conference Paper

References (3)

1. DNA topoisomerase I - Targeted chemotherapy of human colon cancer in xenografts
2. Tolerance of volunteers to cyclosporine A-dilauroylphosphatidylcholine liposome aerosol
3. 9-Nitrocamptothecin liposome aerosol treatment of human cancer subcutaneous xenograft and pulmonary cancer metastases in mice